1138
U N I T 1 2
Musculoskeletal Function
10. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis.
Am J Obstet Gynecol.
2006;194:S3–S11.
11. Rosen CJ. Postmenopausal osteoporosis.
N Engl J Med.
2005;353:595–603.
12. Lambert JK, Zaidi M, Mechanick JI. Male osteoporosis:
epidemiology and the pathogenesis of aging bones.
Curr
Osteoporos Rep.
2011;11(9):229–236.
13. Gennari L, Bilezikian JP. Osteoporosis in men.
Endocrinol Metab
Clin North Am.
2007;36:399–419.
14. Hudec SM, Camacho PM. Secondary osteoporosis.
Endocr
Pract.
2013;19(1):120–128.
15. Russell LA. Osteoporosis and osteomalacia.
Rheum Dis Clin
North Am.
2010;36:665–680.
16. Maricic M. Update on glucocorticoid-induced osteoporosis.
Rheum Dis Clin North Am.
2011;37:415–431.
17. Rothman MS, Bessesen TB. HIV infection and osteoporosis:
pathophysiology, diagnosis, and treatment options.
Curr
Osteoporos Rep.
2012;10(4):270–277.
18. Shaw NJ. Management of osteoporosis in children.
Eur J
Endocrinol.
2008;159:S33–S39.
19. Beals KA, Meyer NL. Female athlete triad update.
Clin Sports
Med.
2007;26:69–80.
20. Sweet MG, Sweet JM, Jeremiah MP, et al. Diagnosis
and treatment of osteoporosis.
Am Fam Physician.
2009;79(3):193–202.
21. Warriner AH, Saag KG. Osteoporosis diagnosis and
medical treatment.
Orthop Clin North Am.
2013;44(2):
125–135.
22. National Osteoporosis Foundation.
Clinician’s Guide to
Prevention and Treatment of Osteoporosis
. Washington, DC:
National Osteoporosis Foundation; 2008.
23. U.S. Preventive Services Task Force. Screening for osteoporosis.
Available at:
uspstf10/osteoporosis/osteors.htm. Accessed September 29,
2013.
24. Katzung BG, Masters SB, Trevor AJ.
Basic & Clinical
Pharmacology
. 12th ed. New York, NY: McGraw-Hill Lange;
2013:782–783.
25. Cauley JA, Robbins J, Chen Z, et al., for the Women’s Health
Initiative. Effects of estrogen plus progestin on risk of fracture
and bone mineral density.
JAMA.
2003;290:1729–1738.
26. Holick MF. Vitamin D deficiency.
N Engl J Med.
2007;357(3):266–281.
27. Holick MF, Chen TC. Vitamin D deficiency: a worldwide
problem with health consequences.
Am J Clin Nutr.
2008;87(suppl):1080D–1086D.
28. Berg EE. Rickets.
Orthop Nurs.
2004;23(1):53–55.
29. Nield LS, Mahajan P, Joshi A, et al. Rickets: not a disease of the
past.
Am Fam Physician.
2006;74:619–630.
30. Mughal MP. Rickets.
Curr Osteoporos Rep.
2011;9:291–299.
31. Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in
children and its management: review of current knowledge and
recommendations.
Pediatrics.
2008;122:398–417.
32. Ralston SH. Paget’s disease of bone.
N Engl J Med.
2013;368(7):644–650.
33. Roodman GD, Windle JJ. Paget disease of bone.
J Clin Invest.
2005;115:200–208.
34. Crowson CS, Matteson EL, Myasoedova E, et al. The
lifetime risk of adult-onset rheumatoid arthritis and other
inflammatory autoimmune rheumatic diseases.
Arthritis Rheum.
2011;63(3):633–639.
35. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis.
N Engl J Med.
2011;365(23):2205–2219.
36. Pedersen M, Jacobsen S, Garred P, et al. Strong combined
gene-environment effects in anti-cyclic citrullinated peptide-
positive rheumatoid arthritis: a nationwide case-control study in
Denmark.
Arthritis Rheum.
2007;56(5):1446–1453.
37. Sweeny SE, Harris ED, Firestein GS. Clinical features of
rheumatoid arthritis. In: Firestein GS, Budd RC, Gabriel
SE, et al., eds.
Kelley’s Textbook of Rheumatology
. 9th ed.
Philadelphia, PA: Elsevier Saunders; 2012:1108–1136.
38. Wasserman AM. Diagnosis and management of rheumatoid
arthritis.
Am Fam Physician.
2011;84(11):1245–1282.
39. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis
classification criteria: an American College of Rheumatology/
European League Against Rheumatism collaborative initiative.
Arthritis Rheum.
2010;62(9):2569.
40. Oliver AM, St. Clair EW. Rheumatoid arthritis: treatment and
assessment. In: Klippel JH, Stone JH, Crofford LJ, et al., eds.
Primer on the Rheumatic Diseases
. 13th ed. New York, NY:
Springer; 2008:133–141.
41. Singh, JA, Furst DE, Bharat A, et al. 2012 update of the 2008
American College of Rheumatology recommendations for the use
of disease-modifying anti-rheumatic drugs and biologic agents
in the treatment of rheumatoid arthritis.
Arthritis Care Res.
2012;64(5):625–639.
42. Pietsky DS. Systemic lupus erythematosus: epidemiology,
pathology, and pathogenesis. In: Klippel JR, Stone JH, Crofford
LJ, et al., eds.
Primer on the Rheumatic Diseases
. 13th ed. New
York, NY: Springer; 2008:303–313.
43. Kumar V, Abbas AK, Fausto N, et al.
Robbins and Cotran
Pathologic Basis of Disease
. 8th ed. Philadelphia, PA: Saunders
Elsevier; 2010:213–226.
44. Schur P, Hahn B. Epidemiology and pathogenesis of systemic
lupus erythematosus. January 2014. Available at:
.
uptodate.com/contents/epidemiology-and-pathogenesis-of-
systemic-lupus-erythematosus#H443498. Accessed February 21,
2014.
45. Dall’era M, Wofsy D. Clinical features of systemic lupus
erythematosus. In: Firestein GS, Budd RC, Gabriel SE, et al., eds.
Kelley’s Textbook of Rheumatology
. 9th ed. Philadelphia, PA:
Elsevier Saunders; 2012:1283–1301.
46. Manzi S, Kao AH. Systemic lupus erythematosus: treatment and
assessment. In: Klippel JR, Stone JH, Crofford LJ, et al., eds.
Primer on the Rheumatic Diseases
. 13th ed. New York, NY:
Springer; 2008:303–313.
47. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma.
N Engl J
Med.
2009; 360:1989–2008.
48. Boin F, Wigley FM. Clinical features and treatment of
scleroderma. In: Firestein GS, Budd RC, Gabriel SE, et al., eds.
Kelley’s Textbook of Rheumatology
. 9th ed. Philadelphia, PA:
Elsevier Saunders; 2012:1366–1395.
49. Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable
multisystem disease.
Am Fam Physician.
2008;78(8):961–969.
50. Buch MH, Seibold JR. Systemic sclerosis: treatment and
assessment. In: Klippel JR, Stone JH, Crofford LJ, et al., eds.
Primer on the Rheumatic Diseases
. 13th ed. New York, NY:
Springer; 2008:359–362.
51. Dougodos M, Baeten D. Spondyloarthritis.
Lancet.
2011;377:2127–2137.
52. Rosenbaum, JT, Davey, MP. Time for a gut check: evidence
for the hypotheses that HLA-B27 predisposes to ankylosing
spondylitis by altering the microbiome.
Arthritis Rheum.
2011;63(11):3195–3198.
53. Elyan M, Khan MA. Diagnosing ankylosing spondylitis.
J Rheumatol Suppl.
2006;33(78):12–23.
54. Clegg DO. Treatment of ankylosing spondylitis.
J Rheumatol
Suppl.
2006;33(78):24–31.
55. Carter JD, Hudson AP. Reactive arthritis: clinical aspects
and medical management.
Rheum Dis Clin North Am.
2009;35:21–44.
56. Fitzgerald O. Psoriatic arthritis. In: Firestein GS, Budd RC,
Gabriel SE, et al., eds.
Kelley’s Textbook of Rheumatology
.
9th ed. Philadelphia, PA: Elsevier Saunders; 2012:1232–1249.
